Development of a multiscale model for the comprehensive assessment of the obese patient, based on an advanced morphofunctional and omic evaluation methodology.
FITME
File: INNEST/2024/240
Duration:
- Start date: 01/09/2024
- Completion date: 21/12/2026
DESCRIPTION
According to the WHO, obesity is a growing pandemic associated with risks such as metabolic syndrome, respiratory diseases, certain types of cancer and musculoskeletal disorders, impacting quality of life and generating high socio-health costs. In this context, Sabartech, specialised in genomic and microbiota analysis, participates in the FITME project (Development of an advanced methodology for comprehensive morphofunctional assessment in obese patients) in the development of an advanced methodology for patients with obesity.
This project, coordinated by the Instituto de Biomecánica de Valencia (IBV), aims to create a multiscale model that combines morphofunctional and omic variables to estimate in a personalised and accurate way the body composition and distribution, as well as the metabolic risk in patients with obesity.
The proposed methodology will be objective, agile, sustainable, non-invasive and not dependent on experts, facilitating its integration into the healthcare environment. SABARTECH will provide its experience in genomic and microbiota analysis, contributing to the development of tools that allow a comprehensive and personalised assessment of patients.
With this initiative, SABARTECH SL continues to consolidate its position as a leading company in the biotechnological field of prevenomics, contributing to the development of advanced methodologies that improve people’s quality of life and strengthen the innovation ecosystem in the Valencian Community.
OBJECTIVES
In order to achieve the purpose of the project, the following specific scientific, technological and technical objectives are proposed:
- To investigate the usefulness of new shape, function and thermography assessment technologies, alone and in combination, for the recording of variables to infer the body composition and distribution of obese people and their association with metabolic risk.
- To identify new genetic and gut microbiota-related biomarkers associated with predisposition to obesity and response to treatment.
- To generate a morphofunctional and omic evaluation methodology adapted to the health care context.
- Development of a multi-scale model for estimating body composition, body distribution and metabolic risk based on the variables recorded through these technologies.
From a strategic point of view, it is expected that the results of the project will have a positive impact on the social and healthcare infrastructure for the management of obesity, as well as favouring the generation of knowledge for the improvement of products and services in this context. This is based on the following specific impact objectives:
- To add value in healthcare processes for the management of obesity: to study ways of implementing and integrating the methodology more optimally in models of the public-private Valencian Health System.
- Through the generation of knowledge, to help companies in the Valencian Community to improve the design of solutions adapted to the needs and requirements of the healthcare context in obesity, and to consider scalability to other populations and pathological conditions.
FINANCING
The FITME project has received a total funding of €811,986.47 from the Valencian Innovation Agency (AVI), distributed in three annual instalments until 2026. This investment will allow progress in the research and development of innovative solutions for the treatment of obesity, a condition that affects a significant percentage of the population and represents a challenge for health systems.
COMPONENTS OF THE CONSORTIUM
Coordinator:
Instituto de Biomecánica de Valencia (IBV)
Collaborating companies and entities
Sabartech S.L.
Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana INCLIVA
Clinicas Ascires (ECG MEDICAS.L.)
With the support of
